- Home
- PRO vs VERV Comparison
PRO vs VERV Comparison
Compare PRO & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRO
- VERV
- Stock Information
- Founded
- PRO 1985
- VERV 2018
- Country
- PRO United States
- VERV United States
- Employees
- PRO N/A
- VERV N/A
- Industry
- PRO EDP Services
- VERV Medicinal Chemicals and Botanical Products
- Sector
- PRO Technology
- VERV Health Care
- Exchange
- PRO Nasdaq
- VERV Nasdaq
- Market Cap
- PRO 863.3M
- VERV 1.0B
- IPO Year
- PRO 2007
- VERV 2021
- Fundamental
- Price
- PRO $15.69
- VERV $10.91
- Analyst Decision
- PRO Strong Buy
- VERV Buy
- Analyst Count
- PRO 10
- VERV 11
- Target Price
- PRO $28.10
- VERV $14.57
- AVG Volume (30 Days)
- PRO 888.5K
- VERV 3.3M
- Earning Date
- PRO 07-31-2025
- VERV 08-07-2025
- Dividend Yield
- PRO N/A
- VERV N/A
- EPS Growth
- PRO N/A
- VERV N/A
- EPS
- PRO N/A
- VERV N/A
- Revenue
- PRO $336,006,000.00
- VERV $59,613,000.00
- Revenue This Year
- PRO $10.27
- VERV $47.32
- Revenue Next Year
- PRO $10.46
- VERV N/A
- P/E Ratio
- PRO N/A
- VERV N/A
- Revenue Growth
- PRO 7.97
- VERV 271.44
- 52 Week Low
- PRO $13.61
- VERV $2.87
- 52 Week High
- PRO $29.84
- VERV $11.41
- Technical
- Relative Strength Index (RSI)
- PRO 46.07
- VERV 73.40
- Support Level
- PRO $14.75
- VERV $11.16
- Resistance Level
- PRO $16.86
- VERV $11.08
- Average True Range (ATR)
- PRO 0.58
- VERV 0.11
- MACD
- PRO 0.03
- VERV -0.25
- Stochastic Oscillator
- PRO 44.55
- VERV 2.27
About PRO PROS Holdings Inc.
Pros Holdings Inc provides software solutions that optimize shopping and selling experiences for both business-to-business and business-to-consumer companies across industry verticals in more than nearly 80 countries. Its PROS Platform is designed to help businesses create, optimize and market available offers and handle orders through both first- and third-party digital channels. The firm generates key revenue form the United States of America, Germany, The rest of Europe, Africa, Asia-Pacific, and Middle East regions.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.